One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).

These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).

The drugs to be administered to patients are:

• JAK-type kinase inhibitors.
• Monoclonal antibodies against TNF.
• Soluble receptor against TNF.
• Biosimilar FAMEb.
• Rituximab.
• Abatacept.
• Drugs that block IL6.

A follow-up will be carried out at 12, 24, 48, 60, 72 and 84 months from the start of treatment, to analyze how the patient's health improves.

Inclusion Criteria:

• Patients aged ≥18 years.
• With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
• Who have received at least one of the doses of the study drugs.
• In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
• With at least two complete evaluations (baseline and final) of clinical variables.

Exclusion Criteria:

• Patients where the medical records lack sufficient baseline and final variables to perform the analysis.
• Patients in whom more than 50% of the variables to be collected are missing in the data collection.

Patients aged > 18 years diagnosed with rheumatoid arthritis, who have been under treatment with at least one dose of the study drugs, whose treatment is followed by the rheumatology unit.